Ivermectin Aristo
Topical ivermectin cream 10 mg/g for the treatment of inflammatory lesions of rosacea in adults
Ivermectin Aristo is a prescription topical cream containing ivermectin 10 mg/g, approved for the treatment of inflammatory papules and pustules of rosacea in adults. Applied once daily to the face, it combines anti-inflammatory and anti-parasitic properties to reduce the visible signs of rosacea. This comprehensive guide covers its uses, correct application, potential side effects, drug interactions, and important safety information based on international medical evidence.
Quick Facts
Key Takeaways
- Ivermectin Aristo cream (10 mg/g) is a once-daily topical treatment specifically approved for inflammatory papules and pustules of rosacea in adults.
- The cream works through a dual mechanism: anti-inflammatory action (reducing cytokine production) and anti-parasitic activity against Demodex folliculorum mites implicated in rosacea.
- Clinical improvement is typically observed within 4 weeks, with maximum benefit at 3–4 months of consistent daily application.
- The most common side effects are mild and localised, including skin burning sensation, irritation, and dryness; serious adverse effects are rare.
- This medication requires a prescription and should be used under medical supervision, with special caution in pregnancy and breastfeeding.
What Is Ivermectin Aristo and What Is It Used For?
Ivermectin Aristo belongs to a class of medications known as anti-parasitic agents, but when formulated as a topical cream at 10 mg/g concentration, it serves a distinct dermatological purpose. It was developed specifically for the treatment of papulopustular rosacea, a chronic inflammatory skin condition that primarily affects the central face, causing persistent redness, visible blood vessels, and inflammatory lesions such as papules and pustules.
Rosacea is a common skin condition affecting an estimated 5% of the global adult population, with higher prevalence in individuals of fair skin and Northern European descent. The condition is often misdiagnosed as acne, eczema, or allergic dermatitis, which can lead to inappropriate treatment. Ivermectin Aristo addresses the two key pathophysiological mechanisms believed to drive papulopustular rosacea: chronic inflammation and the overpopulation of Demodex folliculorum mites on the facial skin.
The active substance, ivermectin, is a semi-synthetic derivative of avermectin, originally discovered in the late 1970s. While oral ivermectin has been widely used for decades to treat parasitic infections such as onchocerciasis (river blindness) and strongyloidiasis, the topical 1% formulation was specifically developed and approved for rosacea. The European Medicines Agency (EMA) approved topical ivermectin for rosacea in 2015, and it has since been adopted in clinical practice guidelines worldwide.
How Does Ivermectin Aristo Work?
Ivermectin Aristo exerts its therapeutic effects through two complementary mechanisms of action. First, it has potent anti-inflammatory properties. In laboratory studies, ivermectin has been shown to inhibit the production of pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which are elevated in rosacea-affected skin. By suppressing this inflammatory cascade, ivermectin reduces the redness, swelling, and discomfort associated with papulopustular lesions.
Second, ivermectin has anti-parasitic activity against Demodex folliculorum and Demodex brevis, two species of microscopic mites that live in human hair follicles and sebaceous glands. Research has consistently demonstrated that patients with papulopustular rosacea harbour significantly higher densities of Demodex mites compared to unaffected individuals. These mites, along with their associated bacteria (particularly Bacillus oleronius), are thought to trigger and perpetuate the inflammatory response characteristic of rosacea. By reducing the Demodex population, ivermectin addresses one of the root contributors to the disease process.
When applied topically, systemic absorption of ivermectin is minimal. Pharmacokinetic studies have shown that steady-state plasma concentrations achieved with daily topical application of 1% ivermectin cream are approximately 100 times lower than those observed with standard oral ivermectin doses used for parasitic infections. This low systemic exposure contributes to the favourable safety profile of the topical formulation.
What Should You Know Before Using Ivermectin Aristo?
Before starting treatment with Ivermectin Aristo, it is essential to have a thorough discussion with your healthcare provider about your medical history, current medications, and any known allergies. While topical ivermectin has a well-established safety profile, certain conditions and circumstances warrant special consideration or may preclude its use entirely.
Contraindications
Ivermectin Aristo should not be used if you have a known hypersensitivity (allergy) to ivermectin or to any of the excipients contained in the cream formulation. Allergic reactions, while rare, can manifest as contact dermatitis, urticaria (hives), or more severe hypersensitivity responses. If you have previously experienced an allergic reaction to any ivermectin-containing product, whether topical or oral, you should inform your doctor before treatment is initiated.
The cream is intended exclusively for adults aged 18 years and older. The safety and efficacy of Ivermectin Aristo have not been established in paediatric populations, and it should not be used in children or adolescents. Additionally, this product is designed solely for topical application to the facial skin and should not be used on other body areas, on broken or irritated skin, or on open wounds.
Warnings and Precautions
Several important precautions should be observed during treatment with Ivermectin Aristo:
- Eye contact: Avoid applying the cream near the eyes, eyelids, lips, mouth, or inside the nostrils. Ivermectin is an eye irritant. If accidental contact occurs, rinse thoroughly with water immediately and seek medical advice if irritation persists.
- Skin irritation: Some patients may experience transient worsening of rosacea symptoms during the initial weeks of treatment. This is sometimes referred to as an initial flare-up and is believed to be related to the die-off of Demodex mites and the resultant immune response. If severe irritation develops, discontinue use and consult your doctor.
- Sun exposure: Rosacea-affected skin is particularly sensitive to ultraviolet (UV) radiation. While ivermectin itself is not photosensitising, patients should continue to practice strict sun protection, including the use of broad-spectrum sunscreen (SPF 30 or higher), wearing wide-brimmed hats, and avoiding prolonged sun exposure.
- Hepatic impairment: Although systemic absorption of topical ivermectin is minimal, patients with severe liver disease should use this medication with caution, as ivermectin is primarily metabolised by the liver. Discuss with your healthcare provider if you have any liver conditions.
- Immunocompromised patients: Individuals with weakened immune systems should use Ivermectin Aristo under close medical supervision, as the immune response to Demodex mite die-off may be altered.
Pregnancy and Breastfeeding
Ivermectin Aristo should not be used during pregnancy unless your doctor considers it clearly necessary. Animal studies at high systemic doses have shown reproductive toxicity, although no adequate human data exist for the topical formulation.
Pregnancy: There are limited data from the use of topical ivermectin in pregnant women. Animal reproductive toxicity studies conducted with oral ivermectin at doses significantly higher than human topical exposure showed adverse effects on foetal development. While the systemic exposure from topical application is very low, the use of Ivermectin Aristo during pregnancy is not recommended as a precaution. Women of childbearing potential should discuss appropriate contraception with their healthcare provider before starting treatment.
Breastfeeding: Ivermectin is excreted in human breast milk following oral administration. Although systemic levels from topical application are very low, a risk to the breastfed infant cannot be entirely excluded. A clinical decision must be made whether to discontinue breastfeeding or to discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If used during breastfeeding, the cream should not be applied to areas that may come into direct contact with the infant.
Fertility: No clinical data are available on the effects of topical ivermectin on human fertility. Animal studies with oral ivermectin at high doses did not indicate any direct harmful effects on fertility parameters.
How Does Ivermectin Aristo Interact with Other Drugs?
One of the advantages of Ivermectin Aristo as a topical formulation is its very low systemic absorption, which significantly limits the potential for drug-drug interactions compared to oral ivermectin. Steady-state plasma levels after topical application are approximately 0.69 ng/mL, which is far below the concentrations achieved with oral dosing. Despite this favourable pharmacokinetic profile, some potential interactions warrant consideration.
No formal drug interaction studies have been conducted with topical ivermectin 10 mg/g cream. However, based on the known pharmacology of ivermectin and the minimal systemic exposure from topical use, the following interactions should be considered:
Major Interactions
| Drug / Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Oral ivermectin | Additive systemic exposure | Moderate | Avoid concurrent use without medical supervision |
| Warfarin and other anticoagulants | Theoretical potentiation (oral ivermectin data) | Low (topical) | Monitor if using concurrent oral anticoagulants |
| CYP3A4 inhibitors (ketoconazole, erythromycin) | Potential increase in ivermectin levels | Low (topical) | Generally safe; inform doctor of all medications |
| Other topical rosacea treatments (metronidazole, azelaic acid) | Potential additive skin irritation | Moderate | Use with medical guidance; separate application times |
Minor Interactions
Cosmetic products, moisturisers, and sunscreens may be used alongside Ivermectin Aristo, but should be applied at different times to avoid dilution of the active ingredient or reduced efficacy. It is generally recommended to apply Ivermectin Aristo first, allow it to absorb for several minutes, and then apply cosmetics or sunscreen as needed. Alcohol-based skin products and harsh chemical exfoliants should be used with caution, as they may exacerbate skin irritation in rosacea-prone skin.
Always inform your healthcare provider and pharmacist of all medications you are taking, including prescription medicines, over-the-counter products, herbal supplements, and topical skincare products, to ensure comprehensive interaction screening.
What Is the Correct Dosage of Ivermectin Aristo?
The dosage of Ivermectin Aristo is straightforward, as the cream is designed for once-daily application. However, correct application technique is important to achieve optimal therapeutic results while minimising the risk of side effects. The following guidelines are based on the approved product information and clinical trial protocols.
Adults
Standard Adult Dosage
Dose: A pea-sized amount (approximately 0.5 g) applied as a thin layer to the affected areas of the face once daily.
Application areas: Five areas of the face may be treated: forehead, chin, nose, left cheek, and right cheek. A pea-sized amount per area is the standard dose.
Duration: Treatment is typically continued for up to 4 months. If lesions recur, treatment may be repeated after assessment by a healthcare provider.
To apply Ivermectin Aristo correctly, begin by washing your face with a gentle, non-irritating cleanser and patting the skin dry. Squeeze a small pea-sized amount of cream onto your fingertip and dot it onto the five treatment areas (forehead, chin, nose, and each cheek). Gently spread the cream in a thin, even layer across each area, avoiding the eyes, lips, and mucous membranes. Wash your hands thoroughly after application.
The cream should be applied at approximately the same time each day. Most patients find it convenient to apply the cream in the evening after their regular skincare routine. Allow the cream to dry before applying any additional skincare products, cosmetics, or sunscreen.
Children
Paediatric Use
Not recommended. The safety and efficacy of Ivermectin Aristo cream have not been established in children and adolescents under 18 years of age. This product should not be used in paediatric patients.
Elderly
Elderly Patients (65 years and older)
No dose adjustment required. Clinical trials included patients up to 86 years of age with no significant differences in safety or efficacy compared to younger adults. Standard dosing applies to elderly patients.
| Patient Group | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Adults (18+) | Pea-sized amount per area | Once daily | Up to 4 months | 5 facial areas; may repeat course |
| Elderly (65+) | Pea-sized amount per area | Once daily | Up to 4 months | No dose adjustment needed |
| Children (<18) | Not applicable | N/A | N/A | Not recommended |
| Hepatic impairment | Standard dose | Once daily | Up to 4 months | Use with caution in severe disease |
| Renal impairment | Standard dose | Once daily | Up to 4 months | No adjustment required |
Missed Dose
If you forget to apply Ivermectin Aristo at your usual time, apply it as soon as you remember on the same day. However, if it is already close to the time for your next scheduled application, skip the missed dose and continue with your regular schedule. Do not apply a double dose to make up for a forgotten application. Occasional missed doses are unlikely to significantly affect treatment outcomes, but consistent daily application is important for achieving the best results.
Overdose
Due to the topical route of administration and low systemic absorption, overdose with Ivermectin Aristo cream is unlikely. If excessive amounts of cream are applied to the face, wipe off the excess with a soft cloth or tissue. If the cream is accidentally ingested, contact a poison control centre or seek medical attention. Symptoms of oral ivermectin overdose may include nausea, vomiting, diarrhoea, hypotension, dizziness, and neurological effects, though these would require ingestion of very large quantities of the topical formulation.
Apply to clean, dry skin. Use only a pea-sized amount per facial zone. Avoid rubbing vigorously — a gentle spreading motion is sufficient. Wait 5–10 minutes before applying moisturiser or sunscreen. Be patient: visible improvement typically begins after 4 weeks of consistent use.
What Are the Side Effects of Ivermectin Aristo?
Like all medicines, Ivermectin Aristo can cause side effects, although not everybody gets them. The topical formulation is generally well tolerated, and most adverse effects are localised to the application site. In clinical trials involving over 2,000 patients treated with topical ivermectin 1% cream, the overall incidence of side effects was comparable to that seen with vehicle cream (placebo), indicating a favourable safety profile.
Side effects are categorised below according to their frequency of occurrence, based on the standard classification used by the European Medicines Agency (EMA) and published clinical trial data:
Common
- Skin burning sensation at the application site
Uncommon
- Skin irritation
- Pruritus (itching) at the application site
- Dry skin (xerosis)
Rare
- Contact dermatitis
- Skin exfoliation (peeling)
- Erythema (redness) worsening
Very Rare / Not Known
- Allergic skin reactions (urticaria, angioedema)
- Transient worsening of rosacea (initial flare)
Understanding the Initial Flare-Up
Some patients may notice a temporary worsening of their rosacea symptoms during the first 1–2 weeks of treatment. This phenomenon is thought to be related to the death of Demodex mites within the skin follicles and the subsequent immune response to the released mite antigens and associated bacteria. The flare-up is typically mild and self-limiting, resolving within a few days to two weeks as the mite population decreases. If the worsening is severe or persistent, discontinue use and consult your prescribing physician.
When to Seek Immediate Medical Attention
- Signs of a severe allergic reaction: widespread rash, difficulty breathing, swelling of the face, lips, tongue, or throat
- Severe skin blistering, ulceration, or open sores at the application site
- Signs of eye irritation if the cream accidentally contacts the eyes and flushing with water does not resolve symptoms
Long-term safety data from clinical trials extending up to 52 weeks have confirmed that topical ivermectin 1% cream maintains a consistent safety profile with no evidence of cumulative toxicity, tachyphylaxis (loss of efficacy), or rebound worsening upon treatment cessation. The low systemic absorption means that the systemic adverse effects associated with oral ivermectin (such as Mazzotti-type reactions seen in the treatment of parasitic infections) are not expected with the topical formulation.
If you experience any side effects not listed here, or if any side effect becomes bothersome or persistent, contact your healthcare provider or pharmacist. You can also report side effects directly to your national medicines regulatory authority to help provide more information on the safety of this medicine.
How Should You Store Ivermectin Aristo?
Proper storage of Ivermectin Aristo is important to maintain the stability and efficacy of the medication throughout its shelf life. The cream should be stored at a temperature not exceeding 30°C (86°F). It should not be frozen, as freezing can alter the formulation’s physical properties and potentially reduce its effectiveness.
Keep the tube tightly closed when not in use to prevent contamination and to maintain the stability of the cream. Store the medication in its original packaging to protect it from light and moisture. As with all medications, Ivermectin Aristo should be kept out of the sight and reach of children.
Do not use the cream after the expiry date stated on the tube and outer carton. The expiry date refers to the last day of that month. After first opening, the cream should be used within the period indicated on the packaging (typically 6 months), regardless of the printed expiry date if this comes later.
Do not dispose of medicines via household waste or wastewater. Return any unused or expired medication to your pharmacist for proper disposal. These measures help to protect the environment and prevent accidental exposure.
What Does Ivermectin Aristo Contain?
Understanding the composition of Ivermectin Aristo can help you identify potential allergens and understand the formulation. The cream contains one active pharmaceutical ingredient and several excipients (inactive ingredients) that form the vehicle for drug delivery.
Active Ingredient
Each gram of cream contains 10 mg of ivermectin (equivalent to a 1% w/w concentration). Ivermectin is a semi-synthetic derivative of avermectin B1, a macrocyclic lactone produced by the soil micro-organism Streptomyces avermitilis.
Excipients (Inactive Ingredients)
The cream base is formulated with several excipients designed to ensure stability, skin penetration, and an acceptable cosmetic feel. Typical excipients in ivermectin 10 mg/g cream formulations include:
- Glycerol — humectant that helps maintain skin moisture
- Isopropyl palmitate — emollient that softens the skin and aids drug absorption
- Carbomer copolymer — thickening agent that provides the cream texture
- Dimethicone — silicone-based emollient for smooth application
- Disodium EDTA (edetic acid) — chelating agent for formulation stability
- Citric acid monohydrate — pH adjuster
- Sodium hydroxide — pH adjuster
- Purified water — solvent base
- Phenoxyethanol — preservative
- Propylene glycol — solvent and humectant (may cause skin irritation in some individuals)
- Oleyl alcohol — emollient and penetration enhancer
- Sorbitan stearate — emulsifier
- Stearyl alcohol — emulsifier and stabiliser (may cause local skin reactions)
- Cetyl alcohol — emulsifier and stabiliser (may cause local skin reactions)
If you have known sensitivities to any of the above excipients, particularly cetyl alcohol, stearyl alcohol, or propylene glycol, inform your doctor before using this product. These ingredients can occasionally cause localised skin reactions in sensitive individuals.
Ivermectin Aristo cream is supplied in aluminium tubes with a polyethylene-lined screw cap. It is available in various pack sizes (typically 15 g, 30 g, and 60 g tubes), though not all sizes may be marketed in every country. The cream is white to slightly yellowish in colour with a smooth, non-greasy texture.
Frequently Asked Questions About Ivermectin Aristo
Ivermectin Aristo is a prescription cream containing 10 mg/g ivermectin, used for the topical treatment of inflammatory lesions (papules and pustules) of rosacea in adults. It works through both anti-inflammatory and anti-parasitic mechanisms to reduce redness, bumps, and pustules associated with rosacea. It is not used for treating acne, eczema, or other skin conditions.
Most patients begin to notice improvement within 4 weeks of starting treatment, though the full therapeutic effect typically takes 3 to 4 months of consistent daily application. In clinical trials, a significant reduction in inflammatory lesion counts was observed at week 12. It is important to continue treatment as prescribed even if early improvement seems slow, as the medication works gradually to reduce both inflammation and Demodex mite populations.
Yes, you can wear makeup while using Ivermectin Aristo. Apply the cream first to clean, dry skin and allow it to absorb for 5 to 10 minutes before applying cosmetics, moisturisers, or sunscreen. Choose non-comedogenic, fragrance-free products designed for sensitive or rosacea-prone skin to minimise the risk of irritation.
No. While both contain the active ingredient ivermectin, Ivermectin Aristo is a topical cream applied to the face specifically for rosacea, whereas oral ivermectin is a tablet used to treat various parasitic infections. The topical cream has very low systemic absorption (approximately 100 times lower blood levels than oral dosing), giving it a different safety profile. They should not be used interchangeably.
Ivermectin Aristo is generally not recommended during pregnancy. Although systemic absorption from topical application is very low, animal studies with oral ivermectin at high doses have shown reproductive toxicity. There are limited human data for the topical formulation. If you are pregnant, planning to become pregnant, or breastfeeding, discuss alternative treatment options with your dermatologist.
If Ivermectin Aristo accidentally comes into contact with your eyes, rinse them immediately and thoroughly with clean water. Ivermectin is an eye irritant and can cause discomfort, redness, and tearing. If irritation persists after thorough rinsing, seek medical advice. To prevent accidental eye contact, avoid applying the cream too close to the eyes and eyelids.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- Stein Gold L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of Drugs in Dermatology. 2014;13(3):316-323.
- Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. British Journal of Dermatology. 2015;172(4):1103-1110. doi:10.1111/bjd.13408
- European Medicines Agency (EMA). Soolantra (ivermectin) — Summary of Product Characteristics. 2015. Updated 2023.
- Schaller M, Gonser L, Rössler U, et al. Application of a rosacea consensus grading system in clinical practice. Journal of the European Academy of Dermatology and Venereology. 2020;34(11):2555-2563.
- Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part II. Topical and Systemic Therapies in the Treatment of Rosacea. Journal of the American Academy of Dermatology. 2015;72(5):761-770. doi:10.1016/j.jaad.2014.08.027
- Forton FMN, De Maertelaer V. Two consecutive standardized skin surface biopsies: an improved sampling method to evaluate Demodex density as a diagnostic tool for rosacea and demodicosis. Acta Dermato-Venereologica. 2017;97(2):242-248.
- National Rosacea Society. Standard Classification and Pathophysiology of Rosacea: The 2017 Update. Journal of the American Academy of Dermatology. 2018;78(1):148-155.
- British National Formulary (BNF). Ivermectin — Topical. National Institute for Health and Care Excellence (NICE). Updated 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. 2023.
- Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR. New developments in the treatment of rosacea — role of once-daily ivermectin cream. Clinical, Cosmetic and Investigational Dermatology. 2016;9:71-77.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specialising in dermatology, clinical pharmacology, and evidence-based medicine.
iMedic Medical Writers — Clinical content specialists with expertise in pharmaceutical information and patient education materials.
iMedic Medical Review Board — Independent panel of dermatology and pharmacology specialists who verify all clinical claims against current evidence.
All content follows the GRADE evidence framework and is reviewed against EMA, FDA, and WHO guidelines. Evidence Level 1A where applicable.
No commercial funding or pharmaceutical sponsorship. Independent medical editorial content. Read our editorial standards.